Status:

COMPLETED

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

Lead Sponsor:

University of Pennsylvania

Collaborating Sponsors:

Baylor Health Care System

Conditions:

Traumatic Brain Injury

Eligibility:

All Genders

18-50 years

Phase:

PHASE2

Brief Summary

Growth Hormone (GH) deficiency, defined by insufficient GH response to a variety of stimulating compounds, is found in 20-35% of adults who suffer traumatic brain injuries (TBI) requiring inpatient re...

Detailed Description

1\. Patient selection and enrollment. Participants will be recruited into the study from subjects admitted for acute inpatient rehabilitation in the North Texas Traumatic Brain Injury Model Systems (N...

Eligibility Criteria

Inclusion

  • Non-penetrating TBI
  • Age 18 - 50 years.
  • Admission to a North Texas Traumatic Brain Injury Model System-affiliated rehabilitation unit within 8 weeks of injury. Enrollment in TBI-MS database not required.
  • Randomization within 2 - 10 weeks of injury.
  • Rancho Los Amigos Rating IV or better at the time of randomization. Should not be at Rancho IV level for more than 4 weeks before randomization.
  • GH deficiency diagnosed by either of the following two criteria:
  • . Peak GH response to L-arginine stimulation test \< 1.4 microg/L; or
  • . Plasma IGF-1 level 1 SD below the expected median for age and body weight.
  • Availability of caregiver to oversee administration of medications.
  • Reasonable expectation for completion of outcome measures
  • Residence inside the United States

Exclusion

  • History of pre-existing neurologic disease (such as epilepsy, brain tumors, meningitis, cerebral palsy, encephalitis, brain abscesses, vascular malformations, cerebrovascular disease, Alzheimer's disease, multiple sclerosis, or HIV-encephalitis)
  • History of premorbid disabling condition that interfere with outcome assessments
  • Contraindication to rhGH therapy. (hypersensitivity to rhGH or any of the components of the supplied product, including metacresol, glycerin, or benzyl alcohol)
  • Penetrating traumatic brain injury
  • Diabetes mellitus.
  • Obesity (BMI \> 30).
  • Active infection.
  • Active malignant disease.
  • Acute critical illness, heart failure, or acute respiratory failure
  • Previous hospitalization for TBI \> 1 day
  • Membership in a vulnerable population (prisoner)
  • Pregnancy. Women of childbearing age will be given a pregnancy test during screening to exclude pregnancy.
  • Lactating females

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

63 Patients enrolled

Trial Details

Trial ID

NCT00766038

Start Date

September 1 2008

End Date

December 1 2013

Last Update

November 18 2019

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Center for NeuroSkills

Bakersfield, California, United States

2

Baylor University Medical Center

Dallas, Texas, United States, 75226

3

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390-9036